Aktis Oncology (AKTS) Fundamental Analysis: Revenue, Earnings & Valuation

8.89 / 10

Outperform

Fundamental analysis scores 8.9/10, highlighting a 63.6% YoY revenue surge, solid inventory turnover (24.96) and fixed‑asset turnover (0.1024). Cost‑of‑sales ratio (74.3%) is favorable, while gross margin hits 100%. Income‑tax ratio (22.35%) is moderate, supporting an Outperform rating.

Analysis Checks(4/6)

Total operating revenue (YoY growth rate %)

Value63.64

Score3/3

Weight30.78%

1M Return1.54%

Inventory turnover ratio

Value24.96

Score2/3

Weight-22.22%

1M Return-1.21%

Gross profit margin (%)

Value100.00

Score1/3

Weight-11.20%

1M Return-0.63%

Income tax / Total profit (%)

Value22.35

Score1/3

Weight-9.12%

1M Return-0.50%

Fixed assets turnover ratio

Value0.10

Score3/3

Weight20.36%

1M Return1.06%

Cost of sales ratio (%)

Value74.31

Score3/3

Weight91.40%

1M Return4.32%

Is AKTS undervalued or overvalued?

AKTS scores 8.89/10 on fundamentals and holds a Discounted valuation at present. Backed by its -29.45% ROE, -980.93% net margin, -15.07 P/E ratio, 5.13 P/B ratio, and -25.42% earnings growth, these metrics solidify its Outperform investment rating.